Minoxidil vs. Finasteride: Which Should You Take for Hair Loss?

If you’ve decided to do something about hair loss and the internet has given you a thousand conflicting answers, the honest version is short. Two drugs have decades of evidence behind them in pattern hair loss: minoxidil and finasteride. They are not alternatives to each other. They are the two halves of the standard regimen, attacking androgenetic alopecia from different angles, and most dermatologists prescribe them together.

This guide explains what each drug actually does, who each is right for on its own, the side-effect tradeoffs, and how the standard combination protocol works.

The short answer

For most men with progressive male pattern hair loss, the standard first-line regimen is both drugs together, because they work on different mechanisms and combine well³ . Finasteride attacks the cause (DHT-driven miniaturisation). Minoxidil counteracts the symptom (shortened growth phase, thinner hair). Used alone, each is a partial solution.

If you can only pick one, the choice depends on what you can tolerate, whether you want a prescription, and whether you’re a man or a woman:

• Men who can take a prescription drug daily: finasteride, because it addresses the underlying cause.
• Men who want over-the-counter only, or can’t tolerate finasteride: topical minoxidil 5%.
• Women with female pattern hair loss: minoxidil 5% topical or 2% topical; finasteride is generally avoided in women of reproductive age and is more nuanced in postmenopausal women, covered in our female pattern hair loss guide.

The rest of this article unpacks why.

What each drug actually does

The two drugs target completely different parts of the hair-loss process, which is why combining them outperforms either alone³ .

Minoxidil: a vasodilator that prolongs growth

Minoxidil was originally a blood-pressure drug. Its hair-growth effect was a side effect, prompting the topical reformulation now sold as Rogaine and generic equivalents⁶ . The current model of how it works in the scalp³ :

• It’s converted to minoxidil sulfate by the enzyme sulfotransferase in the scalp. The sulfate is the active form.
• It prolongs the anagen (growth) phase of the hair cycle, so more follicles spend more time producing hair.
• It increases follicle size, converting some miniaturised vellus hairs into thicker terminal hairs.

What it does not do: lower DHT, slow miniaturisation, or do anything to the underlying genetic process driving pattern hair loss. It compensates for the symptom while you use it.

Finasteride: a 5α-reductase inhibitor that blocks DHT

Finasteride inhibits type II 5α-reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT is the androgen that progressively miniaturises genetically-susceptible follicles, the core mechanism of androgenetic alopecia. At the standard 1 mg/day hair-loss dose, finasteride reduces serum DHT by around 70% and scalp DHT by 60 to 70%⁵ .

Less DHT means less miniaturisation pressure on follicles. In many men this stops further loss, and in some it produces partial recovery of follicles that haven’t fully scarred over.

The mechanistic difference is the entire reason combining the drugs works: finasteride removes the cause, minoxidil rescues the function.

What the trials show

Minoxidil

The Olsen et al. 2002 randomised trial in men with androgenetic alopecia, comparing 5% topical, 2% topical, and placebo over 48 weeks, found¹ :

• 5% topical minoxidil produced significantly greater hair count gains than 2% or placebo.
• About 60% of men showed measurable hair count response.
• Roughly 15 to 20% saw clearly noticeable regrowth, with the rest in the stabilisation-or-modest-thickening band.
• Most of the visible gain occurred in the first 16 to 24 weeks.

Detail and oral minoxidil dosing in our minoxidil complete guide.

Finasteride

The Kaufman et al. 2002 long-term extension followed men on finasteride 1 mg over 5 years² :

• 48% saw improved hair count at year 5 versus baseline
• 42% saw stabilisation (no further loss)
• 10% experienced continued loss despite treatment
• Combined: roughly 90% of men maintained or improved their hair on finasteride over 5 years²

The placebo arm showed continued progressive loss over the same period. Finasteride changed the trajectory in around 9 in 10 men.

Combination therapy

Multiple trials and clinical reviews have shown that combining oral finasteride with topical minoxidil produces greater cosmetic improvement than either drug alone³ . The two work via different mechanisms (DHT blockade plus anagen prolongation), so the effects add rather than overlap. This is why the combination is the default first-line regimen for men with progressive AGA in dermatology practice today.

Head-to-head comparison

Side effects, compared

The side-effect profiles are completely different, which matters when choosing between them or deciding what’s tolerable.

Minoxidil side effects

Mostly local and dose-related³ :

• Scalp irritation, dryness, itching, flaking. Most common. Often related to the propylene glycol vehicle in liquid formulations; foam (which omits propylene glycol) is usually better tolerated.
• Unwanted facial hair, particularly in women. Usually from runoff or hand transfer rather than the scalp itself.
• Initial shedding (“the dread shed”) in the first 4 to 8 weeks as follicles synchronise into a new growth cycle. Normal, not a sign of failure, usually resolves by month 3.

Low-dose oral minoxidil has a different profile (hypertrichosis, mild fluid retention) and requires a prescription. Detail in our minoxidil complete guide.

Finasteride side effects

Mostly systemic and centred on sexual function⁵ :

• Sexual side effects (decreased libido, erectile dysfunction, ejaculatory issues) in roughly 2 to 4% of men in randomised trials, versus 1 to 2% on placebo. Most resolve within weeks to months of stopping.
• Gynecomastia (breast enlargement or tenderness). Uncommon, dose-related.
• Mood changes, including depression. Reported in a small percentage; the causal relationship is debated.
• Reduced semen volume. Common but not typically clinically significant.
• Reduces PSA by ~50%. Important for men undergoing prostate cancer screening: tell any doctor ordering PSA that you’re on finasteride.

There is also post-finasteride syndrome, a contested entity in which sexual, neurological, or emotional symptoms persist after stopping the drug, sometimes for years⁴ . The phenomenon is real for some patients; the frequency, mechanism, and risk factors are still debated. Risk appears small in absolute terms but nonzero. Anyone considering finasteride should be aware of it and stop the drug if persistent unusual symptoms appear.

The honest summary: minoxidil’s downsides are typically nuisances; finasteride’s are more consequential when they happen, but happen to a minority of men.

Who should choose minoxidil only

Reasonable cases for monotherapy with topical minoxidil:

• Women of reproductive age with female pattern hair loss. Finasteride causes severe birth defects in male fetuses and is categorically contraindicated. Minoxidil 5% topical (or 2%) is the standard first-line choice. Spironolactone is the more commonly used systemic option for women, covered in our female pattern hair loss guide.
• Men who can’t or won’t take a prescription drug. Some men aren’t comfortable with the sexual-side-effect profile of finasteride, even at the relatively low rates seen in trials. Topical minoxidil is a reasonable monotherapy in this case, with the understanding that it counteracts the symptom rather than the cause.
• Men with very early or borderline thinning who want a low-commitment first step. Topical minoxidil for 6 to 12 months can buy time and information without committing to a daily oral drug.
• Men who tried finasteride and stopped because of side effects. Topical minoxidil alone is a partial regimen; some clinicians also discuss topical finasteride, which has a different systemic exposure profile.

The honest tradeoff: minoxidil monotherapy is unlikely to halt the underlying progression of AGA. It typically slows visible loss and modestly thickens existing hair while you use it.

Who should choose finasteride only

Less common, but reasonable in specific cases:

• Men who can’t tolerate topical application, find the twice-daily routine unworkable, or have repeated scalp irritation on minoxidil.
• Men whose primary concern is stopping further loss rather than maximising regrowth. Finasteride alone in 5-year data stabilises or improves hair in around 90% of men, which is a strong outcome.
• Men who already have substantial hair on finasteride alone and don’t want to add a second product.

Finasteride monotherapy is a defensible choice. The reason it’s less common in practice is simply that adding minoxidil is cheap, OTC, and pushes outcomes further without adding meaningful risk for most men.

The standard combination protocol

For most men with progressive AGA, the default regimen prescribed by dermatologists looks like this:

• Finasteride 1 mg orally, once daily. Time of day doesn’t matter; consistency does. Brand: Propecia. Generic finasteride is widely available and substantially cheaper.
• Minoxidil 5% topical, twice daily. Foam (1 g) or solution (1 mL) applied to the dry scalp in the affected areas, allowed to dry before bed or styling. Brand: Rogaine. Generic versions are equivalent.
• Realistic timeline: 12 months. Stabilisation is often visible at 3 to 6 months; full assessment of regrowth takes a year. The common mistake is quitting at month 3 because progress isn’t yet dramatic.
• Optional adjuncts: ketoconazole shampoo (mild anti-androgenic, weak evidence), microneedling (small trials suggest it boosts minoxidil response), and switching to oral low-dose minoxidil if topical adherence is poor.

This is “the stack” that r/tressless commenters refer to. It’s not a secret regimen; it’s the standard of care for male AGA, and it works in the majority of men who stick with it for 12 months.

What about topical finasteride?

Topical finasteride 0.25% spray has emerged as a middle-ground option for men who want DHT blockade without full systemic exposure. Recent phase III data shows hair count improvements comparable to oral finasteride 1 mg, with lower serum drug levels and possibly fewer sexual side effects, though long-term data is shorter than for oral.

Detail and dosing in our finasteride vs. dutasteride guide.

When to see a dermatologist

• You’re not sure your diagnosis is pattern hair loss (see our diagnostic guide and types of hair loss guide)
• Sudden, rapid, or patchy loss; scalp redness, scaling, pain, or visible scarring (these point to non-AGA conditions that need different treatment)
• You’re considering oral finasteride for the first time and want a clinician’s read on the risk-benefit conversation
• You’ve used the standard combination correctly for 12 months with no response, in which case escalation (dutasteride, topical finasteride, oral minoxidil) is worth discussing
• Any history of mood disorder, sexual dysfunction, or planned prostate cancer screening, all relevant to the finasteride decision

What this article doesn’t cover

We’ve focused on minoxidil and finasteride for adult men with male pattern hair loss, with brief notes on female use. We haven’t covered the full female pattern hair loss treatment landscape (spironolactone, oral contraceptives, postmenopausal nuance), the use of either drug for non-AGA conditions, or off-label paediatric use. Each warrants its own piece. Topical finasteride is covered in the finasteride vs. dutasteride guide rather than here.

If hair loss is affecting your wellbeing, it’s worth speaking to your GP or a dermatologist, and reaching out to a peer community helps too. You’re not making this up, and you’re not alone in finding it hard. Anything in this article is general education, not personal medical advice.